Cerebellar Assessment in Early Multiple Sclerosis.
Cerebellar impairment is frequent and predictive of disability in multiple sclerosis (MS). The Nine-Hole Peg Test (NHPT) is commonly used to assess cerebellar symptoms despite its lack of specificity for cerebellar ataxia. Eye-tracking is a reliable test for identifying subtle cerebellar symptoms and could be used in clinical trials, including those involving early MS patients. To evaluate, by the use of eye-tracking, the accuracy of the NHPT in detecting subtle cerebellar symptoms in patients with clinically isolated syndrome with a high risk of conversion to MS (HR-CIS). Twenty-nine patients and 13 matched healthy controls (HC) underwent an eye-tracking protocol. Cerebellar impairment was defined by registration of saccadic intrusions or at least 10 % dysmetria in a saccadic movement recording. These criteria were compared to NHPT performance. Sixteen patients fulfilled saccadic criteria for cerebellar impairment. NHPT performance was significantly increased in HR-CIS patients (p < 0.01) versus HC. However, NHPT performance did not differ between cerebellar and non-cerebellar groups. NHPT performance with the dominant hand could differentiate patients, particularly cerebellar patients, from HC, but it could not discriminate cerebellar from non-cerebellar patients who were classified according to saccadic criteria. These findings should be considered in future clinical trials involving HR-CIS patients.
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.|Université de Bordeaux, F-33076, Bordeaux, France.|Neurocentre Magendie, INSERM U1215, F-33077, Bordeaux, France.
Amandine
A
Moroso
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.|Université de Bordeaux, F-33076, Bordeaux, France.|Neurocentre Magendie, INSERM U1215, F-33077, Bordeaux, France.
Aurélie
A
Ruet
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.
Mathilde
M
Deloire
Université de Bordeaux, F-33076, Bordeaux, France.|Neurocentre Magendie, INSERM U1215, F-33077, Bordeaux, France.
Delphine
D
Lamargue-Hamel
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.
Stéphanie
S
Cubizolle
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.
Julie
J
Charré-Morin
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France.
Aurore
A
Saubusse
CHU de Bordeaux, INSERM-CHU CIC-P 0005, & Service de Neurologie, F-33076, Bordeaux, France. bruno.brochet@chu-bordeaux.fr.|Université de Bordeaux, F-33076, Bordeaux, France. bruno.brochet@chu-bordeaux.fr.|Neurocentre Magendie, INSERM U1215, F-33077, Bordeaux, France. bruno.brochet@chu-bordeaux.fr.
Bruno
B
Brochet
D000328:Adult; D002531:Cerebellum / Q000503:physiopathology*; D004185:Disability Evaluation; D018450:Disease Progression; D053483:Eye Movement Measurements; D005260:Female; D006225:Hand / Q000503:physiopathology; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000503:physiopathology*; D062706:Prodromal Symptoms; D011379:Prognosis; D012372:ROC Curve; D012438:Saccades; D012720:Severity of Illness Index
Cerebellum; Eye movements; Multiple sclerosis; Nine-hole peg test